Professor Ben van Hout

Population Health, School of Medicine and Population Health

Professor of Health Economics

b.a.vanhout@sheffield.ac.uk
+44 114 222 0827

Full contact details

Professor Ben van Hout
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
Profile

I joined ScHARR in November 2009 as Professor of Health Economics.

I have extensive experience in modelling and have contributed to the methodology of economic evaluation in various areas. In 1993 I was one of the earliest researchers to apply discrete event models and was the first to apply a non-parametric method to estimate costs in the presence of censoring. In 1994 I was the first to apply Fieller's approach to calculate confidence intervals around cost-effectiveness ratios, and I introduced the acceptability curve, which is now a well-known concept in cost-effectiveness analysis. In 1996 I was one of the first to apply probabilistic sensitivity analysis. In 2000 I was one of the initial people to explore Bayesian techniques in economic evaluation. I have had work published on discounting and estimating utility functions.

I am one of the founding members of the EuroQol group and I currently enjoy chairing the valuation task force within the EQ-5D group. My experience covers several therapeutic areas, including renal disease, cancer, osteoporosis, sepsis, schizophrenia, blood safety and most notably cardiovascular disease. My main interest concerns the use of elegant techniques, mostly to solve practical problems, but sometimes also because of the elegance itself.

Publications

Show: Featured publications All publications

Journal articles

All publications

Journal articles

Chapters

Conference proceedings papers

  • Schneider P, Brazier JE, Devlin N & van Hout B (2022) PCR28 The OPUF Tool: A New Type of Online Survey for Creating Value Sets for the EQ-5D-5L on the Societal-, Group-, and Individual Person Level. Value in Health, Vol. 25(7) (pp S546-S546) RIS download Bibtex download
  • Schneider P, Brazier J, Devlin N & Hout BV (2022) 85:oral The EQ-5D-5L OPUF survey: quantifying health priorities on the individual person level using compositional preference elicitation techniques. Abstracts RIS download Bibtex download
  • Schneider P, Brazier JE, Devlin N & van Hout B (2022) THE OPUF TOOL: A NEW TYPE OF ONLINE SURVEY FOR CREATING VALUE SETS FOR THE EQ-5D-5L ON THE SOCIETAL-, GROUP-, AND INDIVIDUAL PERSON LEVEL. VALUE IN HEALTH, Vol. 25(7) (pp S546-S546) RIS download Bibtex download
  • Schneider P, Van Hout B, Heisen M, Brazier J & Devlin N (2022) A NEW ONLINE TOOL FOR VALUING HEALTH STATES: ELICITING PERSONAL UTILITY FUNCTIONS FOR THE EQ-5D-5L. VALUE IN HEALTH, Vol. 25(1) (pp S13-S13) RIS download Bibtex download
  • Schneider P, Brazier J, van Hout B & Devlin N (2022) Online Elicitation of Personal Utility Functions (OPUF): An Open, Modular Health Valuation Platform. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, Vol. 15(6) (pp 734-734) RIS download Bibtex download
  • Schneider P, Brazier J, van Hout B & Devlin N (2022) The Online elicitation of Personal Utility Functions (OPUF) Tool: a new method to construct (patient) preferences for small groups and on the individual level. QUALITY OF LIFE RESEARCH, Vol. 31 (pp S9-S10) RIS download Bibtex download
  • Schneider P, Brazier JE, Van Hout BA & Devlin N (2022) ONLINE ELICITATION OF PERSONAL UTILITY FUNCTIONS (OPUF) AN OPEN, MODULAR HEALTH VALUATION PLATFORM. VALUE IN HEALTH, Vol. 25(12) (pp S423-S423) RIS download Bibtex download
  • Durno N, Heisen M, Penton H, Schmid R, Ethgen O, Szilvasy Z, Friedel E, Wong O, Charman T, San Jose Caceres A , Muhlbacher AC et al (2022) VALUE-BASED ASSESSMENT OF CLINICAL TRIAL OUTCOMES: A HYPOTHETICAL EXAMPLE USING THE CHILDHOOD AUTISM RATING SCALE IN AUTISM SPECTRUM DISORDER. VALUE IN HEALTH, Vol. 25(12) (pp S444-S444) RIS download Bibtex download
  • Malottki K, Lawson R, Beecroft S, Van Hout BA, Heaton D, Starita C & Patel S (2022) USING LINKED DATABASES TO EXPLORE RESOURCE USE AND REAL-WORLD OUTCOMES IN A RARE DISEASE: POMPE DISEASE IN ENGLAND. VALUE IN HEALTH, Vol. 25(12) (pp S448-S448) RIS download Bibtex download
  • Hartl K, Durno N, Schmid R, Heisen M, Ethgen O, Szilvasy Z, Friedel E, Wong O, Charman T, San Jose Caceres A , Muehlbacher A et al (2021) Preference Study in Childhood Autism Spectrum Disorder (ASD) using the Childhood Autism Rating Scale (CARS2): A Feasibility Assessment. QUALITY OF LIFE RESEARCH, Vol. 30(SUPPL 1) (pp S113-S114) RIS download Bibtex download
  • Schneider P, Van Hout B & Brazier J (2020) FAIR INTERPERSONAL UTILITY COMPARISON IN THE CONTEXT OF HEALTH VALUATION: DESCRIPTION AND FIRST EMPIRICAL EVALUATION OF A NEW MULTI-STEP PREFERENCE AGGREGATION PROCEDURE. MEDICAL DECISION MAKING, Vol. 40(5) (pp E407-E408) RIS download Bibtex download
  • Morrone D, Ricci F, Giulia R, Patti G, Kirchhof P, Kroep S, Chuang L-H, Van Hout B & De Caterina R (2020) Additive predictive power of the cha2ds2-vasc and has-bled scores for mortality in patients with atrial fibrillation. EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol. 22(N) (pp N10-N10) RIS download Bibtex download
  • Lindgren P, Hagström E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Sibartie M & Fonarow GC (2019) PCV40 COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN. Value in Health, Vol. 22 (pp S548-S548) RIS download Bibtex download
  • Lindgren P, Hagstrom E, Van Hout B, Villa G, Urbich M, Sandelin R, Eriksson Svensson M & Fonarow GC (2019) P1225Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden. European Heart Journal, Vol. 40(Supplement_1) RIS download Bibtex download
  • Ray KK, Schoonen M, Annemans L, Van Hout BA, Sibartie M, Bridges I & Bruckert E (2019) P654Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice. European Heart Journal, Vol. 40(Supplement_1) RIS download Bibtex download
  • Diakite I, Lin VW, Klijn S, Navale L, Purdum AG, Fenwick E, Botteman M & van Hout B (2019) TWO-YEAR SURVIVAL WITH AXICABTAGENE CILOLEUCEL IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: AN UPDATED ANALYSIS. HemaSphere, Vol. 3 (pp 817-817) RIS download Bibtex download
  • Fonarow GC, van Hout B, Villa G, Arellano J & Lindgren P (2019) An updated cost-effectiveness analysis of evolocumab therapy for reducing cardiovascular events in very high-risk patients with atherosclerotic cardiovascular disease according to the 2018 ACC/AHA guideline. Journal of Clinical Lipidology, Vol. 13(3) (pp e31-e31) RIS download Bibtex download
  • Diakite I, Lin VW, Klijn S, Navale L, Purdum AG, Fenwick E, Botteman M & van Hout B (2019) MS2 AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL). Value in Health, Vol. 22 (pp S41-S41) RIS download Bibtex download
  • Morrone D, Ricci F, Renda G, Patti G, Kirchhof P, Kroep S, Chuang L-H, Van Hout B & De Caterina R (2019) Additive predictive power of the CHA2DS2-VASc and has bled scores for mortality in patients with atrial fibrillation. EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol. 21(J) (pp J23-J23) RIS download Bibtex download
  • Ray KK, Schoonen M, Annemans L, Van Hout BA, Sibartie M, Bridges I & Bruckert E (2019) Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice. EUROPEAN HEART JOURNAL, Vol. 40 (pp 263-263) RIS download Bibtex download
  • Lindgren P, Hagstrom E, Van Hout B, Villa G, Urbich M, Sandelin R, Svensson ME & Fonarow GC (2019) Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden. EUROPEAN HEART JOURNAL, Vol. 40 (pp 681-681) RIS download Bibtex download
  • Lindgren P, Hagstrom E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Sibartie M & Fonarow GC (2019) COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN. VALUE IN HEALTH, Vol. 22 (pp S548-S548) RIS download Bibtex download
  • Ray K, Bruckert E, Annemans L, Van Hout B, Schoonen M & Bridges I (2018) P1699Characteristics of patients prescribed Evolocumab in Europe. Does clinical use match clinical guidelines?. European Heart Journal, Vol. 39(suppl_1) RIS download Bibtex download
  • Kroep S, Chuang L-H, Cohen A, Gumbs P, van Hout B, Monreal M, Willich SN, Gitt A, Bauersachs R & Agnelli G (2018) The impact of co-morbidity on the disease burden of VTE. Journal of Thrombosis and Thrombolysis, Vol. 46(4) (pp 507-515) RIS download Bibtex download
  • Kroep S, Chuang L, van Hout B, Agnelli G, Gumbs PD, Gitt AK, Monreal M, Bauersachs R, Mismetti P, Willich SN & Cohen AT (2017) The Impact Of Co-Morbidity On The Disease Burden Of VTE. Value in Health, Vol. 20(9) (pp A601-A601) RIS download Bibtex download
  • Chuang L, Cohen AT, Agnelli G, Gumbs PD, Bauersachs R, Kroep S, Mismetti P, Gitt AK, Monreal M, Willich SN & van Hout B (2017) The Comparison of EQ-5D-5L Versus Disease/Treatment-Specific Measures in Pulmonary Embolism and Deep Vein Thrombosis. Value in Health, Vol. 20(9) (pp A623-A623) RIS download Bibtex download
  • Chuang L, van Hout B, Cohen AT, Gumbs PD, Kroep S, Monreal M, Willich SN & Agnelli G (2017) Burden Of Illness Of Deep-Vein Thrombosis In Europe – Healthcare Resource Utilization And Productivity Loss. Value in Health, Vol. 20(9) (pp A612-A612) RIS download Bibtex download
  • Danese M, Villa G, Taylor B, Lindgren P, Van Hout B & Lothgren M (2017) OBSERVED VERSUS PREDICTED CARDIOVASCULAR EVENT RATES IN PRIMARY PREVENTION DIABETIC PATIENTS RECEIVING HIGH-INTENSITY STATINS IN THE UNITED KINGDOM. Journal of the American College of Cardiology, Vol. 69(11) (pp 1852-1852) RIS download Bibtex download
  • Monreal M, Agnelli G, Chuang L, Cohen AT, Gumbs PD, Bauersachs R, Mismetti P, Gitt AK, Kroep S, Willich SN & van Hout B (2017) BURDEN OF ILLNESS OF DEEP VEIN THROMBOSIS IN EUROPE - MORTALITY AND HEALTH RELATED QUALITY OF LIFE. VALUE IN HEALTH, Vol. 20(9) (pp A611-A611) RIS download Bibtex download
  • Chuang L, Gumbs PD, van Hout B, Agnelli G, Cohen AT, Bauersachs R, Mismetti P, Gitt AK, Kroep S, Monreal M , Willich SN et al (2017) BURDEN OF ILLNESS OF PULMONARY EMBOLISM IN EUROPE - MORTALITY AND HEALTH RELATED QUALITY OF LIFE. VALUE IN HEALTH, Vol. 20(9) (pp A611-A611) RIS download Bibtex download
  • Willich SN, Chuang L, van Hout B, Agnelli G, Gumbs PD, Bauersachs R, Mismetti P, Jimenez D, Gitt AK, Kroep S , Monreal M et al (2017) BURDEN OF ILLNESS OF PULMONARY EMBOLISM IN EUROPE - HEALTHCARE RESOURCE UTILIZATION AND PRODUCTIVITY LOSS. VALUE IN HEALTH, Vol. 20(9) (pp A611-A611) RIS download Bibtex download
  • Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, Sorio F, Masana L, Bayes-Genis A & van Hout B (2016) Cost-Effectiveness of Evolocumab in Patients with High Cardiovascular Risk in Spain. Value in Health, Vol. 19(7) (pp A651-A652) RIS download Bibtex download
  • Gumbs PD, Ling-Hsiang Chuang L, Cohen AT, Agnelli G, Willich SN, Monreal M, Jimenez D & van Hout B (2016) The Economic Burden of Pulmonary Embolism in Europe. Value in Health, Vol. 19(7) (pp A365-A365) RIS download Bibtex download
  • Clay E, Jamotte A, Cohen AT, van Hout B, Gumbs PD & Verhamme P (2016) Cost-Effectiveness of Edoxaban Compared to Warfarin for The Treatment and Secondary Prevention of Venous Thromboembolism in The UK. Value in Health, Vol. 19(7) (pp A653-A654) RIS download Bibtex download
  • van Hout B, Gumbs PD, Cohen AT & Verhamme P (2016) An Analysis of the Efficacy and Safety of Edoxaban in Comparison with Rivaroxaban in the Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Value in Health, Vol. 19(7) (pp A637-A638) RIS download Bibtex download
  • Pantiri K, Shah K, Devlin N, Mulhern B & van Hout B (2016) Directly Eliciting Personal Utility Functions From A Convenience Sample Of 30 Health Outcomes Professionals: A Pilot Study. Value in Health, Vol. 19(7) (pp A473-A473) RIS download Bibtex download
  • Stapelkamp C, Byrne B & van Hout B (2016) Adjustment Of OS In Crystal For Post-Study Anti-Cancer Therapies. Value in Health, Vol. 19(7) (pp A394-A394) RIS download Bibtex download
  • Gandra SR, Villa G, Fonarow G, Lothgren M, Lindgren P, Somaratne R & van Hout B (2016) Cost-Effectiveness of LDL-C Lowering With Evolocumab In Patients With High Cardiovascular Risk In The United States. Value in Health, Vol. 19(3) (pp A3-A3) RIS download Bibtex download
  • Shah K, Devlin N, Mulhern B & van Hout B (2015) Directly Eliciting Personal Utility Functions: A New Way To Value Health-Related Quality Of Life. Value in Health, Vol. 18(3) (pp A37-A37) RIS download Bibtex download
  • Villa G, Lothgren M, Gandra SR, Lindgren P & van Hout B (2014) Deterministic Versus Stochastic Prediction of Risk for Cardiovascular Events. Value in Health, Vol. 17(7) (pp A558-A558) RIS download Bibtex download
  • Thomas JA, Tubaro A, Barber N, Thorpe A, Armstrong N, Bachmann A & Van Hout B (2014) 129 Cost effectiveness of XPS vs TURP, a UK analysis. European Urology Supplements, Vol. 13(1) (pp e129-e129) RIS download Bibtex download
  • Begum N, Van Hout B, Thurston S, Schoeman O, Fraschke A & Verheugt FWA (2013) Cost-Effectiveness Analysis of Rivaroxaban in Secondary Prevention of ACS in Sweden. Value in Health, Vol. 16(7) (pp A524-A524) RIS download Bibtex download
  • Krabbe PFM, Devlin NJ, Stolk EA, Shah KK, Oppe M, van Hout B, Quik EH, Pickard AS & Xie F (2013) MULTINATIONAL CONSISTENCY OF A DISCRETE CHOICE MODEL IN QUANTIFYING HEALTH STATES FOR THE EXTENDED 5-LEVEL EQ-5D. VALUE IN HEALTH, Vol. 16(7) (pp A326-A326) RIS download Bibtex download
  • Chuang LH, Treur M, Heeg B, Van Hout B & Filonenko A (2013) The use and impact of value of information analysis in decision-making.. Value Health, Vol. 16(3) (pp A30). United States RIS download Bibtex download
  • Solem CT, Niederman MS, Chastre J, Wan Y, Gao X, Myers DE, Haider S, Chambers R, Li JZ, Van Hout BA & Stephens JM (2012) HEALTH CARE RESOURCE UTILIZATION (HCRU) AND COSTS AMONG PATIENTS TREATED FOR NOSOCOMIAL PNEUMONIA (NP) CAUSED BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA): SECONDARY ANALYSIS OF A MULTI-CENTER RANDOMIZED CONTROLLED STUDY. VALUE IN HEALTH, Vol. 15(4) (pp A10-A10) RIS download Bibtex download
  • Van Hout BA & Oppe M (2011) COMBINING DCE AND TTO INTO A SINGLE VALUE FUNCTION. VALUE IN HEALTH, Vol. 14(7) (pp A238-A239) RIS download Bibtex download
  • Van Hout BA & Stevens JW (2011) THE POWER OF ASSUMPTIONS. VALUE IN HEALTH, Vol. 14(7) (pp A235-A235) RIS download Bibtex download
  • Treur M, Houwing NS, Heeg B, Kristanto P, Botteman M, Vo P, Marx S, Lockhart E & Van Hout B (2010) A CONCEPTUAL FRAMEWORK THAT CAPTURES THE MULTIDIMENSIONAL ASPECT OF ADHERENCE IN A HEALTH-ECONOMIC MODEL: AN APPLICATION IN CHRONIC NONMALIGNANT PAIN MANAGEMENT. VALUE HEALTH, Vol. 13(7) (pp A242-A243) RIS download Bibtex download
  • Thurston S, Webb C, Borgman B & Van Hout B (2010) COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN SWEDEN. VALUE IN HEALTH, Vol. 13(3) (pp A166-A167) RIS download Bibtex download
  • Thurston S, Webb C, Rejas J & Van Hout B (2010) COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME (ACS) PATIENTS IN SPAIN. VALUE HEALTH, Vol. 13(3) (pp A165-A166) RIS download Bibtex download
  • Van Hout BA, Botteman M & Dukler A (2010) THE VALUE OF A PREDICTIVE DIAGNOSTIC BLOOD TEST IN MULTIPLE SCLEROSIS (MS). VALUE HEALTH, Vol. 13(3) (pp A137-A137) RIS download Bibtex download
  • Gu NY, Bell C, Botteman M & Van Hout BA (2010) COMPARING THE TIME TRADEOFF (TTO), THE VISUAL ANALOGUE SCALE (VAS) AND THE EQ-5D VALUE-SETS IN PATIENTS TREATED WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN). VALUE HEALTH, Vol. 13(3) (pp A212-A212) RIS download Bibtex download
  • Gu NY, Bell C, Botteman M & Van Hout BA (2010) ASSOCIATION BETWEEN SELF-REPORTED NEUROPATHIC PAIN SEVERITY AND THE EQ-5D IN PATIENTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN). VALUE HEALTH, Vol. 13(3) (pp A213-A213) RIS download Bibtex download
  • Gu NY, Bell C, Botteman M & Van Hout BA (2010) ASSESSING THE IMPACT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN) RELATED HEALTH IMPAIRMENT ON LOSS OF PRODUCTIVE TIME (LOPT). VALUE HEALTH, Vol. 13(3) (pp A61-A61) RIS download Bibtex download
  • Bojke C, Cifaldi M, Ray S & Van Hout B (2010) MAINTENANCE OF PHYSICAL FUNCTION IMPROVES EMPLOYMENT STATUS OVER TIME FOR PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. RHEUMATOLOGY, Vol. 49 (pp I72-I73) RIS download Bibtex download
  • Logman F, Heeg B, Botteman M, Kaura S & van Hout B (2009) Economic Evaluation of Zoledronic Acid for the Prevention of Osteoporotic Fractures in Post-Menopausal Women with Early Breast Cancer Receiving Aromatase Inhibitors in the United Kingdom. CANCER RESEARCH, Vol. 69(24) (pp 574S-574S) RIS download Bibtex download
  • Thurston SJ, Webb K, Ong S, Meerding WJ & van Hout BA (2009) COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE NETHERLANDS. VALUE HEALTH, Vol. 12(7) (pp A335-A335) RIS download Bibtex download
  • Heeg BMS, Treur MJ & van Hout BA (2009) HANDLING UNCERTAINTY IN THE CASE OF COMBINED END-POINTS. VALUE HEALTH, Vol. 12(7) (pp A235-A235) RIS download Bibtex download
  • On MMLL, Heeg BMS, De Charro F & van Hout BA (2009) COMPARISON OF THREE META-MODELS FOR UNCERTAINTY ANALYSIS. VALUE HEALTH, Vol. 12(7) (pp A235-A235) RIS download Bibtex download
  • van Hout BA (2009) THE VALUE OF ADDED LIFE YEARS AS A FUNCTION OF AGE, PROGNOSIS AND QUALITY OF LIFE. VALUE HEALTH, Vol. 12(3) (pp A4-A5) RIS download Bibtex download
  • van Hout BA (2009) THE POWER OF ASSUMPTIONS. VALUE HEALTH, Vol. 12(3) (pp A34-A34) RIS download Bibtex download
  • Leen C, Thuresson PO, Hegg B, Vardeva K, Gosden T, Yogaratnam JZ & Van Hout B (2009) Cost-effectiveness of atazanavir compared to lopinavir in treatment-naive HIV-1 patients in Scotland. HIV MED, Vol. 10 (pp 41-42) RIS download Bibtex download
  • Logman JFS, Treur MJ, Verheggen BG, Heeg BMS, Stephens JM, Haider S, Cappelleri JC, Nathwani D, Tice A & Van Hout BA (2008) ASSESSING ANTIMICROBIAL SUCCESS RATES IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI): A BAYESIAN META-ANALYSIS. VALUE HEALTH, Vol. 11(6) (pp A428-A428) RIS download Bibtex download
  • Verheggen BG, Heeg BMS, Vos CBJ & Van Hout BA (2008) COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS AMPHOTERICIN B, VORICONAZOLE, AND ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS. VALUE HEALTH, Vol. 11(6) (pp A437-A437) RIS download Bibtex download
  • Verheggen BG, Treur MJ, Heeg BMS, Botteman MF, Van Hout BA & Trocio JN (2008) ESTIMATING THE QUALITY OF LIFE IMPACTS OF TOLTERODINE AND TAMSULOSIN TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER. VALUE HEALTH, Vol. 11(6) (pp A655-A655) RIS download Bibtex download
  • Thuresson PO, Heeg B, Neubauer AS, Intorcia M & Van Hout BA (2008) COST EFFECTIVENESS ANALYSIS OF REYATAZ (R) VERSUS KALETRA (R) IN THE TREATMENT OF NAIVE HIV PATIENTS IN ITALY. VALUE HEALTH, Vol. 11(6) (pp A351-A351) RIS download Bibtex download
  • Thurston SJ, Thompson RP, Ong S & van Hout BA (2008) COST EFFECTIVENESS OF HIGH DOSE ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE UK. VALUE HEALTH, Vol. 11(6) (pp A405-A405) RIS download Bibtex download
  • Logman JFS, Treur MJ, Verheggen BG, Heeg BMS, Stephens J, Spiesser J, Simoneau D, Haider S, Nathwani D & Van Hout BA (2008) A BAYESIAN META-ANALYSIS OF THE EFFICACY OF SIX ANTIMICROBIAL AGENTS FOR CONFIRMED STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT-TISSUE INFECTIONS (CSSTIS). VALUE HEALTH, Vol. 11(6) (pp A428-A428) RIS download Bibtex download
  • Treur MJ, Heeg B, Moller HJ, Schmeding A & Van Hout BA (2008) A pharmacoeconomic analysis of schizophrenic patients switching from branded to generic risperidone involving a possible compliance loss. VALUE HEALTH, Vol. 11(3) (pp A118-A118) RIS download Bibtex download
  • Treur MJ, McCracken F, Heeg B, Joshi AV, Thurston S, Verbeggen B, Marc B, de Charro F & van Hout B (2007) Efficacy of recombinant activated factor VII (rFVlla) vs. activated prothrombin complex concentrate (APCC) in patients with hemophilia with inhibitors: A Bayesian meta-analysis. BLOOD, Vol. 110(11) (pp 59B-59B) RIS download Bibtex download
  • Van der Steen A, Verheggen BG, Heeg BMS & Van Hout BA (2007) Dealing with competing causes of death, illness and costs: The Disease Elimination Life Table Analysis (DELTA) model. VALUE HEALTH, Vol. 10(6) (pp A454-A454) RIS download Bibtex download
  • Damen J, Heeg BMS, Lothgren M & Van Hout BA (2007) A pharmacoeconomic analysis of compliance gains on antipsychotic medications. VALUE HEALTH, Vol. 10(6) (pp A294-A294) RIS download Bibtex download
  • Damen J, Heeg B, Lothgren M & Van Hout BA (2007) The cost effectiveness of paliperidone extended-release OROS in Sweden, Finland, Denmark and Norway. VALUE HEALTH, Vol. 10(6) (pp A294-A295) RIS download Bibtex download
  • Van der Steen A, Heeg B, De Charro F & Van Hout BA (2007) Spatial interpolation. VALUE HEALTH, Vol. 10(6) (pp A453-A453) RIS download Bibtex download
  • Treur MJ, McCraken F, Heeg BMS, Joshi AV, Botteman MF, De Charro F & Van Hout BA (2007) Recombinant activated factor VII (RFVIIA)vs. activated prothrombin complex concentrate (APCC) for on-demand treatment of joint bleeds in hemophiliacs with inhibitors: A systematic review and Bayesian meta-regression survival model with time-dependent covariates. VALUE HEALTH, Vol. 10(6) (pp A284-A285) RIS download Bibtex download
  • Damen J, Heeg BMS, Lothgren M & Van Hout BA (2007) The cost-effectiveness of risperidone long-acting injectable in Sweden. VALUE HEALTH, Vol. 10(6) (pp A293-A294) RIS download Bibtex download
  • Borkent-Raven BA, Janssen MP, De Wit A, Koedijk FD, Van Hout BA & Van der Poel CL (2007) Costs and effects of HBV-NAT screening in the Netherlands. TRANSFUSION, Vol. 47(3) (pp 266A-266A) RIS download Bibtex download
  • Borkent-Raven BA, Janssen MP, Van Hout BA & Van der Poel CL (2007) The fate of blood components: Distributions of patients to whom they are transfused, their age and diagnoses. TRANSFUSION, Vol. 47(3) (pp 268A-269A) RIS download Bibtex download
  • Logman F, Heeg B, Botteman MF, Marfatia AA & Van Hout BA (2007) Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: Application to the United Kingdom. EJC SUPPLEMENTS, Vol. 5(4) (pp 156-156) RIS download Bibtex download
  • Janssen MP, Van der Poel CL, Schaasberg WP, Bonsel GJ & Van Hout BA (2006) Ten years of blood transfusions: Use, disease and survival. TRANSFUSION, Vol. 46(9) (pp 153A-154A) RIS download Bibtex download
  • Janssen MP, van der Poel CI, Schaasberg W, Bonsel GJ & Van Hout BA (2006) Ten years of blood transufsions: Use, disease and survival. VOX SANG, Vol. 91 (pp 319-319) RIS download Bibtex download
  • Botteman MF, Hay JW, Van Hout BA, Curry A, Wong R & Luo MP (2006) Cost effectiveness of adalimumab therapy vs. conventional care in the United Kingdom (UK) patients with active ankylosing spondylitis (AS). ANNALS OF THE RHEUMATIC DISEASES, Vol. 65 (pp 207-208) RIS download Bibtex download
  • Klok RM, Postma MJ, Van Hout BA & Brouwers JR (2005) All proton pump inhibitors are equivalent for treatment of GERD. CLEV CLIN J MED, Vol. 72(12) (pp 1100-1100) RIS download Bibtex download
  • Van Hout B (2005) Cost effectiveness of fondaparinux compared with enoxaparin for extended prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery using Dutch estimates of costs. VALUE HEALTH, Vol. 8(6) (pp A116-A116) RIS download Bibtex download
  • Van Hout B (2005) Cost effectiveness of extended prophylaxis with fondaparinux to prevent venous thromboembolism in patients undergoing hip fracture surgery using UK and Dutch estimates of costs. VALUE HEALTH, Vol. 8(6) (pp A116-A116) RIS download Bibtex download
  • Heeg B, Buskens E, Ingham M, Caleo S, Rabinowitz J & Van Hout B (2005) A discrete event simulation (DES) model to describe schizophrenia. VALUE HEALTH, Vol. 8(6) (pp A207-A207) RIS download Bibtex download
  • Cohen DJ, Dulisse B, Ryan JW, de Bruyne B, Van Hout BA & Serruys PW (2005) Cost-effectiveness of PCI with or without drug-eluting stents vs. bypass surgery for treatment of multivessel coronary disease: 1-year results from the ARTS I and ARTS II trials. CIRCULATION, Vol. 112(17) (pp U612-U612) RIS download Bibtex download
  • Heeg BM, Buskens E, Serra AV, Palha AP, Teixeira JM, Figueira L, Jara J & van Hout B (2004) Costs and effects of Risperdal Consta (TM) in comparison to conventional depot and shortacting atypical formulations in Portugal. VALUE HEALTH, Vol. 7(6) (pp 778-778) RIS download Bibtex download
  • Heeg BMS, Buskens E & van Hout BA (2004) The costs and effects of clopidogrel in comparison to ASA or placebo for several patient populations in Denmark. VALUE HEALTH, Vol. 7(6) (pp 642-642) RIS download Bibtex download
  • Verschuuren M, van Hout BA & Bonsel GJ (2004) VIOLATIONS OF THE ADDITIVE ASSUMPTION IN THE STANDARD QALY APPROACH: EXTRA-MAXIMAL TRADE OFFS. QUALITY OF LIFE RESEARCH, Vol. 13(9) (pp 1570-1570) RIS download Bibtex download
  • Verschuuren M, van Hout BA & Bonsel GJ (2004) MODELING TIME TRADE OFF VALUATIONS: IN SEARCH OF A GOOD FIT. QUALITY OF LIFE RESEARCH, Vol. 13(9) (pp 1499-1499) RIS download Bibtex download
  • Heeg BM, Emmermann A, Laux G, Moller HJ, Naber D & Van Hout BA (2003) Costs and effects of risperdal Consta (TM) in comparison to conventional depot and short-acting atypical formulations in Germany. VALUE HEALTH, Vol. 6(6) (pp 692-692) RIS download Bibtex download
  • van Hout BA, Tangelder MJD, Bervoets P & Gabriel S (2003) Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation in the Netherlands. VALUE HEALTH, Vol. 6(6) (pp 667-668) RIS download Bibtex download
  • Azar A, Hoes A, Arends L, Van den Voorde-Rosenbrand K, Bots M, van Hout B, Lubsen J & Grobbee D (2003) Efficacy of treatment of hypertension: A meta-analysis of 68,000 patients and its implications for current practice. JOURNAL OF HYPERTENSION, Vol. 21 (pp S115-S115) RIS download Bibtex download
  • Lamfers EJ, Schut A, Hooghoudt TE, Hertzberger DP, Stolwijk PW, Boersma E, Verheugt FWA & Van Hout BA (2003) Cost-effectiveness of prehospital thrombolysis. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 41(6) (pp 524A-524A) RIS download Bibtex download
  • Van Gestel A, Bakker J, Van Hout B & Veraart C (2002) The costs of severe sepsis - The Netherlands, 2000. VALUE HEALTH, Vol. 5(6) (pp 561-561) RIS download Bibtex download
  • Van Gestel A, Bakker J, Veraart C & Van Hout B (2002) Incidence of severe sepsis in the Netherlands: A point prevalence survey. VALUE HEALTH, Vol. 5(6) (pp 576-576) RIS download Bibtex download
  • Heeg BM, van Aalst G, van den Arend IJ, Mehnert A & van Hout B (2002) A discrete events model of long-term outcomes and cost of treatment with long acting risperidone in schizophrenia. VALUE HEALTH, Vol. 5(6) (pp 515-516) RIS download Bibtex download
  • Heeg BM, van Aalst GD, Mehnert A & van Hout B (2002) Simulating the course of schizophrenia using discrete events modelling. VALUE HEALTH, Vol. 5(6) (pp 524-524) RIS download Bibtex download
  • Lindeboom WK, van Hout BA, Serruys PWS, Unger F, Taeymans Y, van Nooten G, Pieper M & Maass D (2002) Working status after CABG and stented angioplasty: results from the ARTS study. EUROPEAN HEART JOURNAL, Vol. 23 (pp 260-260) RIS download Bibtex download
  • van Hout BA, Lindeboom WK, Morice MC, de Jong P, Molnar F, Wijns W, Holubarsch C, Bartorelli A & RAVEL investigators (2002) Cost-effectiveness of the sirolimus eluting Bx-VELOCITY stent: 1-year results. EUROPEAN HEART JOURNAL, Vol. 23 (pp 691-691) RIS download Bibtex download
  • Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard GR, van Hout B & PROWESS Investigators (2002) Cost-effectiveness of drotrecogin alfa (activated) (Xigris (TM)) in severe sepsis. CRIT CARE MED, Vol. 30(2) (pp 493-493) RIS download Bibtex download
  • Linde-Zwirble WT, Clermont G, Van Hout B, Ball DE, Basson BR & Angus DC (2001) Increased survivorship with drotrecogin alfa (activated) in the treatment of severe sepsis: The effect on hospital costs. CRIT CARE MED, Vol. 29(12) (pp A1-A1) RIS download Bibtex download
  • Abizaid A, Costa M, Centemero M, Abizaid A, Legrand VMG, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AGMR , Sousa JE et al (2001) Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: Insights from the arterial revascularization therapy study (ARTS) trial.. AM J CARDIOL, Vol. 88(5A) (pp 4G-4G) RIS download Bibtex download
  • Sheiban I (2001) Stenting is less expensive than bypass surgery for multivessel coronary disease but is associated with repeat revascularization. Evidence-based Cardiovascular Medicine, Vol. 5(3) (pp 94-95) RIS download Bibtex download
  • Lindeboom WK, Van Hout BA, Backx B, Unger F, Sousa JE, Jatene A, Bonnier JJRM, Schoenberger JPAM, Buller N & Bonser R (2000) Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in diabetic patients with multivessel disease. CIRCULATION, Vol. 102(18) (pp 550-550) RIS download Bibtex download
  • Disco CMC, Lindeboom WK, Serruys PW, Unger F, Legrand V, Limet R, van Herwerden L, Carere R, Lichtenstein S & van Hout BA (2000) Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in patients with multi-vessel disease assessed by age. EUR HEART J, Vol. 21 (pp 478-478) RIS download Bibtex download
  • Lindeboom WK, Serruys PW, Unger F, Schuler G, Mohr FW, Roose PCH, van Geldrop THR, Morel MAM, Disco CMC & van Hout BA (2000) Quality of life after CABG and stented angioplasty: results from the ARTS study. EUR HEART J, Vol. 21 (pp 221-221) RIS download Bibtex download
  • De Bruyne B, Serruys PW, Carlier S, van Hout B, van Sonsbeek JM, Gurne O, Pijls NHJ, Ziekenhuis C, Belardl JA, Germonprez JL , Schofield PM et al (1999) Debate II: A randomized comparison of cost-effectiveness of primary versus provisional stenting. CIRCULATION, Vol. 100(18) (pp 790-791) RIS download Bibtex download
  • Van Os N, Niessen LW, Casparie AF & Van Hout BA (1999) Cost-effectiveness analysis of national clinical guidelines. DIABETES, Vol. 48 (pp A416-A416) RIS download Bibtex download
  • Serruys PW, Unger F, van Herwerden L, Mohr F, Simon R, Albrechts C, Wijns W, van Hout B, van Es GA, Hugenholtz PG & Morel MA (1998) Arterial revascularisation therapy study: The ARTS study, a randomised trial of bypass-surgery versus stenting in multivessel coronary disease.. CIRCULATION, Vol. 98(17) (pp 498-498) RIS download Bibtex download
  • Heeschen C, Hamm CW, Goldmann BU, Wohlrath S, van Hout BA & Simoons ML (1998) Cost effectiveness of abciximab in patients with unstable angina according to the troponin T status. CIRCULATION, Vol. 98(17) (pp 358-359) RIS download Bibtex download
  • van Hout B, Gagnon D & McNulty P (1998) Assessing the probability of economic dominance without data from a head to head trial. MED DECIS MAKING, Vol. 18(4) (pp 489-489) RIS download Bibtex download
  • van Hout BA, Bowman L, Zelinger DJ & Simoons ML (1998) Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. EUROPEAN HEART JOURNAL, Vol. 19 (pp D59-D66) RIS download Bibtex download
  • van Hout BA, Cohen DJ, Koens BAH & Serruys PW (1998) Costs and effects of stent implantation versus balloon angioplasty. J AM COLL CARDIOL, Vol. 31(2) (pp 50A-50A) RIS download Bibtex download
  • DeLaet CEDH, vanHout B, Burger H, Hofman A & Pols HAP (1997) Cost-effectiveness of hip fracture prevention: The later the better?. J BONE MINER RES, Vol. 12 (pp F558-F558) RIS download Bibtex download

Reports

  • Devlin NJ, Shah KK, Feng Y, Mulhern B & van Hout B (2016) Valuing health-related quality of life: An EQ-5D-5L value set for England RIS download Bibtex download
  • Ara R, Kearns B, Mukuria C, van Hout B & Brazier JE (2013) Examining productivity losses associated with health related quality of life using patient and general population data. View this article in WRRO RIS download Bibtex download
  • ara R, van hout B, Kearns B & Brazier JE (2013) Case-mix methodology for the NHS outcomes framework GP Patient Survey Questionnaire Data View this article in WRRO RIS download Bibtex download

Posters

  • Schneider P, van Hout B, Heisen M, Brazier JE & Devlin N (2022) P60 A New Online Tool for Valuing Health States: Eliciting Personal Utility Functions for the EQ-5D-5L. RIS download Bibtex download

Working papers

Other

Preprints